 MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. 